BR112023018832A2 - Composições de proteínas de fusão quiméricas modificadas e métodos de uso das mesmas - Google Patents

Composições de proteínas de fusão quiméricas modificadas e métodos de uso das mesmas

Info

Publication number
BR112023018832A2
BR112023018832A2 BR112023018832A BR112023018832A BR112023018832A2 BR 112023018832 A2 BR112023018832 A2 BR 112023018832A2 BR 112023018832 A BR112023018832 A BR 112023018832A BR 112023018832 A BR112023018832 A BR 112023018832A BR 112023018832 A2 BR112023018832 A2 BR 112023018832A2
Authority
BR
Brazil
Prior art keywords
modified
methods
compositions
chimerical
fusion proteins
Prior art date
Application number
BR112023018832A
Other languages
English (en)
Inventor
Daniel Getts
Yuxiao Wang
Original Assignee
Myeloid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myeloid Therapeutics Inc filed Critical Myeloid Therapeutics Inc
Publication of BR112023018832A2 publication Critical patent/BR112023018832A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/04—Hydrolases acting on acid anhydrides (3.6) acting on acid anhydrides; involved in cellular and subcellular movement (3.6.4)
    • C12Y306/04013—RNA helicase (3.6.4.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

composições de proteínas de fusão quiméricas modificadas e métodos de uso das mesmas. composições e métodos para produzir e usar células modificadas, tais como células mieloides modificadas que expressam uma proteína de fusão quimérica que apresenta um domínio de ligação capaz de se ligar a moléculas de superfície em células alvo, tais como células doentes.
BR112023018832A 2021-03-17 2022-03-17 Composições de proteínas de fusão quiméricas modificadas e métodos de uso das mesmas BR112023018832A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163162352P 2021-03-17 2021-03-17
US202163172922P 2021-04-09 2021-04-09
US202163243947P 2021-09-14 2021-09-14
US202163255540P 2021-10-14 2021-10-14
PCT/US2022/020787 WO2022197949A2 (en) 2021-03-17 2022-03-17 Engineered chimeric fusion protein compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112023018832A2 true BR112023018832A2 (pt) 2023-12-26

Family

ID=83322358

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023018832A BR112023018832A2 (pt) 2021-03-17 2022-03-17 Composições de proteínas de fusão quiméricas modificadas e métodos de uso das mesmas

Country Status (11)

Country Link
US (1) US12030938B2 (pt)
EP (1) EP4308133A2 (pt)
JP (1) JP2024512004A (pt)
KR (1) KR20240013094A (pt)
AU (1) AU2022237618A1 (pt)
BR (1) BR112023018832A2 (pt)
CA (1) CA3212398A1 (pt)
GB (1) GB2623191A (pt)
IL (1) IL305950A (pt)
MX (1) MX2023010916A (pt)
WO (1) WO2022197949A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023177821A2 (en) * 2022-03-16 2023-09-21 Myeloid Therapeutics, Inc. Binding domains and methods of use thereof

Family Cites Families (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1975A (en) 1841-02-12 Manner of constructing corn-shellers
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JPH06500014A (ja) 1990-07-25 1994-01-06 シンジーン，インコーポレイテッド 多数の核酸相補体を生成させる環状伸長法
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
US5773244A (en) 1993-05-19 1998-06-30 Regents Of The University Of California Methods of making circular RNA
FR2709309B1 (fr) 1993-08-25 1995-11-10 Centre Nat Rech Scient Compositions cellulaires, préparation et utilisations thérapeutiques.
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5641875A (en) 1993-09-30 1997-06-24 University Of Pennsylvania DNA encoding chimeric IgG Fc receptor
US5639642A (en) 1994-06-16 1997-06-17 Novo Nordisk A/S Synthetic leader peptide sequences
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5766903A (en) 1995-08-23 1998-06-16 University Technology Corporation Circular RNA and uses thereof
US6734014B1 (en) 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
WO1998005795A1 (en) 1996-08-02 1998-02-12 The Center For Blood Research, Inc. Enrichment of dendritic cells from blood
AU2872199A (en) 1998-02-20 1999-09-06 Rockefeller University, The Apoptotic cell-mediated antigen presentation to dendritic cells
US6936468B2 (en) 2000-04-28 2005-08-30 University Of Pittsburgh Use of tolerogenic dendritic cells for enhancing tolerogenicity in a host and methods for making the same
US7176243B2 (en) 2000-06-02 2007-02-13 The General Hospital Corporation CaR receptor as a mediator of migratory cell chemotaxis and/or chemokinesis
AU2001297703B2 (en) 2000-11-07 2006-10-19 City Of Hope CD19-specific redirected immune cells
JP2005530695A (ja) 2002-02-15 2005-10-13 ザイコス インク． 生理活性物質を細胞内に導入するエレクトロポレーション法
EP2301356A3 (en) 2002-12-04 2012-05-30 Baylor Research Institute Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors
WO2005019429A2 (en) 2003-08-22 2005-03-03 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
US7709625B2 (en) 2004-06-10 2010-05-04 The Board Of Regents Of The University Of Texas Methods and compositions for bone marrow stem cell-derived macrophage delivery of genes for gene therapy
UA94019C2 (ru) 2004-07-09 2011-04-11 Чугаи Сейяку Кабусики Кайся Антитело, которое специфически связывается с глипиканом 3 (gpc3)
WO2006022407A1 (ja) 2004-08-24 2006-03-02 Chugai Seiyaku Kabushiki Kaisha 抗グリピカン３抗体を用いたアジュバント療法
AU2005299379B2 (en) 2004-10-25 2011-06-09 Cellerant Therapeutics, Inc. Methods of expanding myeloid cell populations and uses thereof
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
US7625724B2 (en) * 2005-08-25 2009-12-01 Board Of Regents, The University Of Texas System MAVS in the prevention and treatment of viral diseases
US20090191202A1 (en) 2005-09-29 2009-07-30 Jamieson Catriona Helen M Methods for manipulating phagocytosis mediated by CD47
AU2007232356A1 (en) 2006-04-03 2007-10-11 Keele University Targeted therapy
EP2046347A2 (en) 2006-07-20 2009-04-15 Gourmetceuticals, LLC Phosphorylated glucomannan polysaccharide for receptor mediated activation and maturation of monocyte-derived dendritic cells
US7833789B2 (en) 2006-08-01 2010-11-16 Fondazione Centro San Raffaele Del Monte Tabor Monocyte cell
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
ES2582340T3 (es) 2008-01-15 2016-09-12 The Board Of Trustees Of The Leland Stanford Junior University Métodos para manipular fagocitosis mediada por CD47
AU2009273251B2 (en) 2008-07-22 2014-12-18 Ablynx Nv Amino acid sequences directed against multitarget scavenger receptors and polypeptides
JP6133538B2 (ja) 2008-09-22 2017-05-24 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ Ｃｄ４０およびパターン認識受容体アダプターを誘発することによる免疫応答を生成するための方法および組成物
EP2248903A1 (en) 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages
EP2332994A1 (en) 2009-12-09 2011-06-15 Friedrich-Alexander-Universität Erlangen-Nürnberg Trispecific therapeutics against acute myeloid leukaemia
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
JP5975983B2 (ja) 2010-04-16 2016-08-23 ベリカム ファーマシューティカルズ， インコーポレイテッド 固形腫瘍を処置するための方法
WO2012005763A1 (en) 2010-07-06 2012-01-12 The Scripps Research Institute Use of myeloid-like progenitor cell populations to treat tumors
ES2754394T3 (es) 2010-09-08 2020-04-17 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Receptores de antígenos quiméricos con una región bisagra optimizada
WO2012043651A1 (ja) 2010-09-30 2012-04-05 国立大学法人 熊本大学 ミエロイド系血液細胞の製造方法
AU2012267531B2 (en) 2011-06-08 2017-06-22 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
WO2013051718A1 (ja) 2011-10-07 2013-04-11 国立大学法人三重大学 キメラ抗原受容体
US9149519B2 (en) 2012-01-17 2015-10-06 New York University Chimeric human immunodeficiency virus type 1 (HIV-1) with enhanced dendritic cell and macrophage tropism comprising the simian immunodeficiency virus (SIV) minimal Vpx packaging domain
US20140140989A1 (en) 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
ES2743203T3 (es) 2012-02-06 2020-02-18 Inhibrx Inc Anticuerpos CD47 y métodos de uso de los mismos
US8647616B2 (en) 2012-02-14 2014-02-11 Loma Linda University Agents and method for treating inflammation-related conditions and diseases
EP2639313A1 (en) 2012-03-14 2013-09-18 Rheinische Friedrich-Wilhelms-Universität Bonn High-resolution transcriptome of human macrophages
EP2855666B1 (en) 2012-05-25 2019-12-04 Cellectis Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
CN103483452B (zh) 2012-06-12 2021-08-13 上海细胞治疗集团有限公司 双信号独立的嵌合抗原受体及其用途
EP2892930B1 (en) * 2012-09-07 2019-08-14 University Of Miami Fusion proteins for promoting an immune response, nucleic acids encoding same, and methods of making and use thereof
WO2014055668A1 (en) 2012-10-02 2014-04-10 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
EP2953643B1 (en) 2013-02-06 2023-02-22 Inhibrx, Inc. Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
WO2014121840A1 (en) 2013-02-07 2014-08-14 Medizinische Hochschule Hannover Induced dendritic cells and uses thereof
SE537429C2 (sv) 2013-02-14 2015-04-28 Scania Cv Ab Samtidig skattning av åtminstone massa och rullmotstånd förett fordon
RS60759B1 (sr) 2013-02-26 2020-10-30 Memorial Sloan Kettering Cancer Center Sastavi i postupci za imunoterapiju
WO2014153114A1 (en) 2013-03-14 2014-09-25 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
WO2014145252A2 (en) 2013-03-15 2014-09-18 Milone Michael C Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
BR112016009898A2 (pt) 2013-10-31 2017-12-05 Hutchinson Fred Cancer Res células-tronco/progenitoras hematopoiéticas e efetoras não-t modificadas e usos das mesmas
KR20230007559A (ko) 2013-12-20 2023-01-12 프레드 허친슨 캔서 센터 태그된 키메라 이펙터 분자 및 그의 리셉터
KR102088169B1 (ko) 2013-12-25 2020-03-12 다이이찌 산쿄 가부시키가이샤 항 trop2 항체-약물 컨쥬게이트
SG11201607143UA (en) 2014-03-11 2016-09-29 Univ Leland Stanford Junior Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
JP2017522028A (ja) 2014-07-16 2017-08-10 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 環状ポリヌクレオチド
WO2016016343A1 (en) 2014-07-31 2016-02-04 Cellectis Ror1 specific multi-chain chimeric antigen receptor
RU2724999C2 (ru) 2014-08-19 2020-06-29 Новартис Аг Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей
CA2959141A1 (en) 2014-08-28 2016-03-03 Bioatla, Llc Conditionally active chimeric antigen receptors for modified t-cells
US20180133252A9 (en) 2014-09-09 2018-05-17 Unum Therapeutics Inc. Chimeric receptors and uses thereof in immune therapy
MX2017004007A (es) 2014-09-28 2018-05-07 Univ California Modulacion de celulas mieloides estimulantes y no estimulantes.
WO2016055551A1 (en) 2014-10-07 2016-04-14 Cellectis Method for modulating car-induced immune cells activity
MA41538A (fr) 2014-10-17 2017-12-26 Baylor College Medicine Cellules immunitaires bipartites et tripartites de signalisation
KR20170074235A (ko) 2014-10-31 2017-06-29 메사추세츠 인스티튜트 오브 테크놀로지 면역 세포로의 생체분자의 전달
MX2017006485A (es) 2014-11-18 2018-03-23 Janssen Pharmaceutica Nv Anticuerpos anti-cd47, metodos y usos.
WO2016090312A1 (en) 2014-12-05 2016-06-09 Memorial Sloan-Kettering Cancer Center Chimeric antigen receptors targeting g-protein coupled receptor and uses thereof
IL253149B2 (en) 2014-12-29 2023-11-01 Novartis Ag Methods for preparing cells expressing a chimeric receptor antigen
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
CA2975851A1 (en) 2015-02-06 2016-08-11 National University Of Singapore Methods for enhancing efficacy of therapeutic immune cells
US10577669B2 (en) 2015-02-11 2020-03-03 Loma Linda University Method for utilizing engineered dendritic cells to induce gut-homing regulatory T cells and treat gut inflammation
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
EP4091616A1 (en) 2015-02-27 2022-11-23 iCell Gene Therapeutics LLC Chimeric antigen receptors (car) targeting hematologic malignancies, compositions and methods of use thereof
EP3270936A4 (en) 2015-03-17 2018-08-08 Chimera Bioengineering Inc. Smart car devices, de car polypeptides, side cars and uses thereof
MA41962A (fr) 2015-04-23 2018-02-28 Baylor College Medicine Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t
US10434153B1 (en) 2015-05-20 2019-10-08 Kim Leslie O'Neill Use of car and bite technology coupled with an scFv from an antibody against human thymidine kinase 1 to specifically target tumors
GB201509413D0 (en) 2015-06-01 2015-07-15 Ucl Business Plc Fusion protein
EP3302558A4 (en) 2015-06-01 2019-01-16 The Rockefeller University ANTICANCER AGENTS AND METHODS OF USE
US11376326B2 (en) 2015-07-01 2022-07-05 Chugai Seiyaku Kabushiki Kaisha GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective
US20190008897A1 (en) 2015-07-22 2019-01-10 University Of Washington Compositions and methods for producing pro-inflammatory macrophages
CN108025024B (zh) 2015-07-28 2022-11-29 宾夕法尼亚大学董事会 表达嵌合抗原受体的修饰单核细胞/巨噬细胞及其用途
US11352439B2 (en) 2015-08-13 2022-06-07 Kim Leslie O'Neill Macrophage CAR (MOTO-CAR) in immunotherapy
CA2997912A1 (en) 2015-09-09 2017-03-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Genetic engineering of macrophages for immunotherapy
BR112018005620A2 (pt) 2015-09-22 2018-10-09 Univ Wuerzburg J Maximilians método para transferência de gene estável e de nível elevado em linfócitos
EP3334764A2 (en) 2015-10-13 2018-06-20 Brigham Young University Macrophage chimeric antigen receptor (moto-car) in imunotherapy
WO2017083441A1 (en) 2015-11-09 2017-05-18 Aperisys, Inc. Modified immune cells and uses thereof
US10946042B2 (en) 2015-12-01 2021-03-16 The Trustees Of The University Of Pennsylvania Compositions and methods for selective phagocytosis of human cancer cells
EP3202783A1 (en) 2016-02-02 2017-08-09 Ecole Polytechnique Federale de Lausanne (EPFL) Engineered antigen presenting cells and uses thereof
WO2017133175A1 (en) 2016-02-04 2017-08-10 Nanjing Legend Biotech Co., Ltd. Engineered mammalian cells for cancer therapy
WO2017136633A1 (en) 2016-02-04 2017-08-10 Duke University Cell-based vaccine compositions and methods of use
CA3016552A1 (en) 2016-03-15 2017-09-21 Genentech, Inc. Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
US20180186855A1 (en) 2016-03-23 2018-07-05 Alector Llc Chimeric receptors and methods of use thereof
AU2017244108B2 (en) 2016-03-29 2021-03-18 University Of Southern California Chimeric antigen receptors targeting cancer
US10875919B2 (en) 2016-04-26 2020-12-29 Alector Llc Chimeric receptors and methods of use thereof
US11225515B2 (en) 2016-08-26 2022-01-18 Agency For Science, Technology And Research Macrophage stimulating protein receptor (or RON—recepteur d'Origine Nantais) antibodies and uses thereof
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
JP2019536471A (ja) 2016-09-27 2019-12-19 セロ・セラピューティクス・インコーポレイテッドＣＥＲＯ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． キメラエンガルフメント受容体分子
US20190263928A1 (en) 2016-09-30 2019-08-29 Baylor College Of Medicine Adaptive chimeric antigen receptor t-cell design
WO2018071058A1 (en) 2016-10-15 2018-04-19 Baylor College Of Medicine Platform for enhanced targeted cell delivery
WO2018073394A1 (en) 2016-10-19 2018-04-26 Cellectis Cell death inducing chimeric antigen receptors
BR112019008702A2 (pt) 2016-11-01 2019-07-16 Genmab B.V. polipeptídeo, método de diminuição de uma função fc efetora de um polipeptídeo, composição, método de tratamento, kit de partes, e, uso de um polipeptídeo ou composição.
CA3049791A1 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
EA201991632A1 (ru) 2017-02-28 2020-03-12 Аффимед Гмбх Комбинация антитела против cd16a с цитокином
IL311608A (en) 2017-03-13 2024-05-01 Poseida Therapeutics Inc Preparations and methods for the selective elimination and replacement of hematopoietic stem cells
US20200216506A1 (en) 2017-05-12 2020-07-09 Children's Medical Center Corporation Nucleic acids that manipulate immune pathways
US10415017B2 (en) 2017-05-17 2019-09-17 Thunder Biotech, Inc. Transgenic macrophages, chimeric antigen receptors, and associated methods
WO2018231871A1 (en) 2017-06-12 2018-12-20 Emory University T-cell antigen targeted chimeric antigen receptor (car) and uses in cell therapies
WO2019005641A1 (en) 2017-06-25 2019-01-03 Systimmune, Inc. GUIDING AND NAVIGATION CONTROL PROTEINS AND METHODS OF PRODUCTION AND USE THEREOF
EP3664845A4 (en) 2017-08-08 2021-03-10 Pionyr Immunotherapeutics, Inc. COMPOSITIONS AND METHODS OF DEACTIVATION OF MYELOID CELLS EXPRESSING TREM1
CN111479921B (zh) 2017-09-18 2024-08-02 埃克苏马生物技术公司 用于以基因方式修饰且扩增淋巴细胞以及调节其活性的方法及组合物
JP7382922B2 (ja) 2017-09-20 2023-11-17 中外製薬株式会社 Ｐｄ－１系結合アンタゴニストおよびｇｐｃ３標的化剤を使用する併用療法のための投与レジメン
AU2018341244A1 (en) 2017-09-26 2020-03-05 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules and methods of use
WO2019070704A1 (en) 2017-10-02 2019-04-11 Georgia Tech Research Corporation METHODS AND COMPOSITIONS FOR ENGINEERING SYNTHESIS BIOLOGICAL SWITCHES FOR REMOTE CONTROL OF BIOLOGICAL ACTIVITY
GB201717974D0 (en) 2017-10-31 2017-12-13 Univ Court Of The Univ Of Aberdeen Modified receptors
CN109971716B (zh) 2017-12-28 2023-08-01 上海细胞治疗研究院 自分泌cd47抗体的egfr特异性car-t细胞及其用途
WO2019152781A1 (en) 2018-02-02 2019-08-08 The Trustees Of The University Of Pennsylvania Modified monocytes/macrophages/dendritic cells expressing chimeric antigen receptors and uses in diseases and disorders associated with protein aggregates
GB2572005A (en) 2018-03-16 2019-09-18 Univ Court Univ Of Edinburgh Macrophage-based therapy
WO2019191332A1 (en) 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Chimeric engulfment receptors and uses thereof for neurodegenerative diseases
EP3774906A1 (en) 2018-03-28 2021-02-17 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
CN112218887A (zh) 2018-03-28 2021-01-12 森罗治疗公司 细胞免疫疗法组合物及其用途
US12054529B2 (en) 2018-04-20 2024-08-06 Medizinische Hochschule Hannover Chimeric antigen receptor and CAR-T cells that bind a herpes virus antigen
CA3098865A1 (en) 2018-05-02 2019-11-07 The Trustees Of The University Of Pennsylvania Compositions and methods of phospholipase a2 receptor chimeric autoantibody receptor t cells
EP3628309A1 (en) 2018-09-28 2020-04-01 Universität Heidelberg Method of making oral dosage forms
GB201818110D0 (en) 2018-11-06 2018-12-19 Macrophox Ltd Monocytes for cancer targeting
WO2020097193A1 (en) 2018-11-06 2020-05-14 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
CA3124467A1 (en) 2018-12-19 2020-06-25 The Trustees Of The University Of Pennsylvania Use of cd2/5/7 knock-out anti-cd2/5/7 chimeric antigen receptor t cells against t cell lymphomas and leukemias
US20220378824A1 (en) 2019-04-30 2022-12-01 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
US20220001031A1 (en) 2019-04-30 2022-01-06 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof
EP3962497A4 (en) 2019-04-30 2023-01-18 Myeloid Therapeutics, Inc. MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
US11026973B2 (en) 2019-04-30 2021-06-08 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
JP2022536684A (ja) 2019-06-11 2022-08-18 マイエロイド・セラピューティクス，インコーポレーテッド マクロファージ特異的エンゲージャー組成物およびその使用方法
GB2628935A (en) 2019-09-03 2024-10-09 Myeloid Therapeutics Inc Methods and compositions for genomic integration
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
GB2608279B (en) 2019-12-11 2024-08-28 Myeloid Therapeutics Inc Therapeutic cell compositions and methods for manufacture and uses thereof
BR112022011957A2 (pt) 2019-12-20 2022-09-06 Medimmune Llc Composições e métodos de tratamento de câncer com receptores de antígenos quiméricos visando glipicana 3
CN115667500A (zh) 2020-03-18 2023-01-31 优特力克斯有限公司 Gpc3 car-t细胞组合物及其制备和使用方法
JP2023525991A (ja) 2020-05-07 2023-06-20 フェインズ セラピューティクス，インコーポレーテッド 抗腫瘍関連抗原抗体及びその使用
IL298693A (en) 2020-06-04 2023-02-01 Carisma Therapeutics Inc New structures for chimeric antigen receptors
CA3187138A1 (en) 2020-06-26 2021-12-30 Carisma Therapeutics Inc. Mrna transfection of immune cells
WO2022036265A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Chimeric tim receptors and uses thereof
MX2023003424A (es) 2020-09-24 2023-05-03 Flagship Pioneering Innovations V Inc Composiciones y metodos para inhibir la expresion genica.
KR20230084533A (ko) 2020-10-09 2023-06-13 페이트 세러퓨틱스, 인코포레이티드 조작된 iPSC 및 보강된 면역 효과기 세포
JP2023549140A (ja) 2020-11-04 2023-11-22 マイエロイド・セラピューティクス，インコーポレーテッド 操作されたキメラ融合タンパク質組成物およびその使用方法
CN117083301A (zh) 2021-02-03 2023-11-17 先声再明医药有限公司 特异性识别磷脂酰肌醇蛋白聚糖3的单克隆抗体及其应用
CA3217047A1 (en) 2021-04-28 2022-11-03 Sanquin IP B.V. Chimeric fc-alpha receptors and uses thereof
WO2022236049A1 (en) 2021-05-07 2022-11-10 Senti Biosciences, Inc. Chimeric antigen receptors and methods of use
WO2023030539A1 (en) 2021-09-06 2023-03-09 Nanjing Legend Biotech Co., Ltd. Anti-gpc3 chimeric antigen receptor and methods of use thereof
AU2023232822A1 (en) 2022-03-08 2024-09-05 Synthekine, Inc. Orthogonal gpc3 chimeric antigen receptor t cells

Also Published As

Publication number Publication date
IL305950A (en) 2023-11-01
WO2022197949A3 (en) 2022-11-10
US12030938B2 (en) 2024-07-09
WO2022197949A2 (en) 2022-09-22
MX2023010916A (es) 2023-12-14
EP4308133A2 (en) 2024-01-24
AU2022237618A1 (en) 2023-10-12
KR20240013094A (ko) 2024-01-30
GB202314244D0 (en) 2023-11-01
US20230303684A1 (en) 2023-09-28
JP2024512004A (ja) 2024-03-18
CA3212398A1 (en) 2022-09-22
GB2623191A (en) 2024-04-10

Similar Documents

Publication Publication Date Title
BR112018068189A2 (pt) proteínas de ligação induzíveis e métodos de uso
CL2022003788A1 (es) Moléculas de unión contra bcma y usos de las mismas
CL2022000300A1 (es) Muteínas de interleucina 21 y sus usos para tratar tumores sólidos (divisional de la solicitud no. 202000252)
MX2023005201A (es) Composiciones de proteinas de fusion quimerica modificadas por ingenieria y metodos de uso de las mismas.
CO2019006485A2 (es) Anticuerpos y metodos de su utilizacion
EA202092093A1 (ru) Композиции и способы перепрограммирования tcr с применением слитых белков
BR112019006384A2 (pt) enzimas modificadoras de ácido nucleico guiadas por rna e métodos de uso das mesmas
MX2021003435A (es) Moleculas inmunomoduladoras localizadas en el colageno y metodos de las mismas.
EP4275698A3 (en) Anti-tigit antibodies and methods of use thereof
BR112021005769A2 (pt) proteínas de ligação a dll3 e métodos de uso
BR112021021843A8 (pt) Composições de proteínas de fusão quiméricas modificadas e método de uso das mesmas
NZ756763A (en) Engineered transferrin receptor binding polypeptides
EA201892561A1 (ru) Гибридные белки gdf15 и их применение
DK202300015Y9 (da) Ikke-animalsk baserede proteinkilder med funktionelle egenskaber
BR112019004711A2 (pt) receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
BR112021022666A2 (pt) Frações de separação e seus métodos e uso
BR112017004675A2 (pt) receptores quiméricos e usos dos mesmos em terapia imunológica
EA201890137A1 (ru) Среда для культивирования клеток с добавлением таурина и способы применения
BR112018000477A2 (pt) proteína de ligação de imunoglobulina não natural, composição, uso da proteína de ligação de ig não natural, método de purificação de afinidade de imunoglobulinas, método de geração de uma proteína de ligação de imunoglobulina não natural, molécula de ácido nucleico, vetor, célula hospedeira ou um hospedeiro não humano, e método para a produção de uma proteína de ligação de imunoglobulina não natural
BR112019000693A2 (pt) composições de muc1- car e métodos para uso
DOP2014000083A (es) Inmunoenlazadores dirigidos contra el tnf
ECSP099688A (es) Moléculas y métodos para modular la pro-proteína
BR112015021866A2 (pt) Domínios de gla como agentes direcionadores
WO2019056023A3 (en) Claudin6 antibodies and methods of treating cancer